anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present application relates to the design and synthesis of prodrugs of novel positively charged polypeptides and related compounds having the structure of the general formula (1) &#39;Structure 1&#39;. The compound represented by the general formula (1) &#39;Structure 1&#39; can be prepared by standard polypeptide synthesis methods. The positively charged amino groups of the polypeptide prodrug molecule not only render the drug soluble in water, but also bind to the negative charge on the phosphate head group of the biofilm to push the drug into the cytoplasm. The lipophilic moiety in the prodrug molecule (by modification of the polar group with a lipophilic alkyl group) will facilitate entry of the drug into the skin membrane. Experimental results show that more than 40% of the prodrug can switch back to the parent peptide structure in a few minutes. The prodrug can even easily cross the blood brain barrier. Transdermal drug delivery systems for polypeptides and related compounds may enable the use of polypeptide hormones in the medical field. Another great benefit of transdermal administration of these prodrugs is that administration is more convenient, particularly to children.
PROBLEM TO BE SOLVED: To obtain the subject composition having high ameliorating effect on dirty blood, namely high effect having dense blood and high viscosity and improving conditions having bad fluidity by including Enkianthus perulatus as a main ingredient. SOLUTION: This composition contains Enkianthus perulatus as a main ingredient. The grass is preferably used by extracting whole grass of Enkianthus perulatus with water or a lower alcohol under heating and powdering the extract so as to make administrable form. Combined use of Enkianthus perulatus and leaf of Salvia miltiorrhiza which is a labiate is preferable because of large ameliorating effect on dirty blood. Further, Mucunae caulis, root of Dalbergia odorifera T. Chen, Crateagi fructus, Curcumae rhizoma, Cinnamonome cortex, Zingiberis rhizoma, Citri leiocarpae exocarpium and Ginseng radix can be formulated. Enkianthus perulatus is preferably formulated in an amount of &gt;=40wt.% and Salvia miltiorrhiza is preferably formulated in an amount of &lt;=15wt.%. Other components such as root of Dalbergia odorifera T. Chen and Crateagi fructus are each formulated in an amount of &lt;=10wt.%.  Furthermore, the composition has effects on increase of cerebral blood flow, blood lipid, etc., and can safely be administered.
PURPOSE:To obtain an analgesic having excellent analgesic activity and useful for the mitigation of cancer pain, rheumatic pain, arthritic pain, etc., by using a diterpenoid as an active component. CONSTITUTION:A diterpenoid of formula (R&lt;1&gt; and R&lt;2&gt; are independently H or hydroxyl; R&lt;3&gt; is H or acetoxy) is used as an active component or the objective agent. It is used as a drug for oral administration (e.g. tablet, capsule or powder) together with a conventional drug carrier or as an injection together with pH- modifier, buffering agent, etc. The active component compound of formula is produced by drying the leaf of Rabdosia trichocarpa (a plant of genus Isodon, family Labiatae), extracting with an organic solvent (e.g. ether or chloroform) at an arbitrary temperature between room temperature and refluxing temperature, concentrating the extract, washing the concentration residue with water to remove sugars and separating the objective component by column chromatography packed with silica gel, etc.
FIELD: chemistry.SUBSTANCE: invention relates to the field of macrolide chemistry, namely to previously unknown compounds – 5,4&#39;&#39;-bis[(aryl)amino](thioxo) acetates of ivermectin of the general formula I (1 a-j) having antiparasitic activity, as well as to the method for their preparation and antiparasitic agents based on them. Method is that the ivermectin of formula III is reacted with acid chloride in an organic solvent medium in the presence of an amine type catalyst, followed by isolation of produced 5,4&#39;&#39;-bis(chloroacetyl)ivermectin and treatment with its pre-prepared solution of sulfur and amine in DMF. As the organic solvent, for example, methylene chloride or chloroform is used. As the amine type catalyst, for example, pyridine, 2,6-lutidine or triethylamine is used. To improve the solubility of sulfur and to create a homogeneous reaction medium, triethylamine is added to the previously prepared sulfur and amine solution in DMF. Invention also relates to antiparasitic agents based on compounds of general formula I. 1a-jR=,,,,,,,III.EFFECT: technical result of the proposed invention consists in the preparation of new compounds of general formula I possessing high antiparasitic activity, allowing them to be used to create effective antiparasitic agents compatible with auxiliary substances ointments, which widens the range of anti-parasitic products that can be used for external use in the fight against parasites.8 cl, 1 tbl, 11 ex
The present invention discloses a medicine for hemostasis, blood stasis removal and coaptation, which is prepared from 17 kinds of medicines, such as frankincense, rhubarb, dragon&#39;s blood, angelica, borax, myrrh, ground beetle, drynaria, cinnabar, safflower, native copper, catechu, dipsacus root, notoginseng, borneol, scorpion, Chinese ephedra, etc. The medicines are ground into powders after being mixed. The medicine is externally applied while orally taken by patients. The medicine can treat traumatic injuries, such as incised wounds, gunshot wounds, contusion, stremma, etc., fractures and old fractures, and especially have bone regeneration effect on old fractures. The medicine has the functions of hemostasis, acesodyne, blood activation, blood stasis removal, channels and collaterals dredging, fracture setting, and cold and dampness elimination. The effective rate and the cure rate of the medicine for treating traumatic injuries respectively reach 100% and 99%; the effective rate and the cure rate of the medicine for the coaptation for fracture patients respectively reach 99% and 98%, without toxic or side effect.
The invention relates to the testing of humans or other animals, such as horses, cattle or dogs, for allergic reaction or hypersensitivity to penicillins. The tests can be used both to predict and to diagnose allergy. The invention comprises new materials for use in minor determinant mixture (MDM) compositions and lyophilized, storage-stable MDM compositions and novel test methods employing such materials. The new MDM materials are N-penicilloyl amines of an aliphatic amine or  alpha -aminoacid having the following molecular structure:   &lt;IMAGE&gt;   wherein: R1=a side chain which defines the type of penicillin-e.g., where R1=    &lt;IMAGE&gt;   the new material is a derivative of benzylpenicillin; and R2 is an alkyl group of C2-C6 length, preferably ethyl or propyl, or an aminoacid residue as described herein. The tests are preferably carried out by applying solutions of the materials to the skin of the patient or other test animal and pricking or scratching the skin, or by injecting the materials intradermally, and then observing for wheal and flare reactions. The preferred test method comprises a two-solution test using a solution of the novel PPL preparations described in my copending U.S. Patent application Ser. No. 898,044 applied on or into one area of the patient&#39;s skin and a separate solution containing the new minor determinant material alone or as part of an MDM solution with other constituents applied on or into another area of the patient&#39;s skin.
This invention relates to compositions for carrying physiologically active agents through body membranes. Many physiologically active agents are best applied topically to obtain desirable results. The greatest problem in applying physiologically active agents topically is that the skin is such an effective barrier to penetration. Vehicles such as USP cold cream, ethanol and various ointments, oils, solvents, and emulsions have been used heretofore to apply physiologically active ingredients locally. Most such vehicles are not effective to carry significant amounts of physiologically active agents through the skin. The present invention relates to compositions useful in topically administering a physiologically active agent to a human or animal comprising the agent and an effective, non-toxic amount of a compound having the structural formula Where R&#39; is H or a lower alkyl group having 1-4 carbon atoms, m is 3-7,n is 0-17, and R is -CH3 , or where R&#34; = H or Halogen and R&#39; has the same meaning as above, with the provisio that if m + 3 and R + -CH3 then n is no 0-4.
Diethylamine salicylate monohydrate is prepared by mixing together salicylic acid, diethylamine, water and acetone, and cooling to-15 DEG C. Hydrates of diethylamine 2-hydroxy-m-toluate and diethylamine 2, 5-dihydroxybenzoate are prepared by evaporating an aqueous solution of the amine salt to a thick syrup, cooling to crystallizing point, filtering off the crystals obtained, and then draining and air-drying the crystals.  Specification 790,762 is referred to.ALSO:Pharmaceutical compositions suitable for the treatment of rheumatic disorders comprise a solid or liquid solution of salicylamide in a solvent consisting of or containing an amine salt of an hydroxy aromatic acid of the formula &lt;FORM:0976393/A5-A6/1&gt; where any one of the five substituents R1, R2, R3, R4 and R5 is an -OH group, the remaining four being hydrogen, -OH groups or alkyl groups with not more than three carbon atoms, R6 is an alkyl group with not more than two carbon atoms, and R7 and R8 are hydrogen or alkyl groups with not more than two carbon atoms.  The compositions may include water and water-miscible solvents such as alcohols, glycols and polyoxyethylene glycols.  The compositions may be in the form of simple solid or liquid solutions, and also emulsions, ointments, pastes, sprays or jellies.  Amine salts specified are diethylamine salicylate, diethylamine 2,5-dihydroxybenzoate and diethylamine 2-hydroxy-m-toluate. Optional ingredients mentioned in some of the examples are ethyl nicotinate (a rubefacient) together with neroli perfume.  According to the Provisional Specification, the amide active ingredient can be any substituted benzamide having at least one hydroxy group and, optionally, one or more lower alkyl groups in the benzene ring.  Specification 790,762 is referred to.
PURPOSE:To obtain an external dermatic drug having improved transcutaneous absorbability of a cationic water-soluble drug, by adding a specific ionic absorbefacient and nonionic absorbefacient to a base. CONSTITUTION:The objective external dermatic drug having improved transcutaneous absorbability of the principal drug can be produced by adding (A) a cathionic water-soluble drug (e.g. flurazepam hydrochloride) as a principal drug, (B) an ionic absorbefacient selected from an anionic surfactant (e.g. alkylsulfuric acid) and an ampholytic surfactant (e.g. alkyl betaine) and (C) a nonionic absorbefacient selected from polyoxyethylene alkyl ether, urea, pantothenic acid derivative and sucrose fatty acid ester to the drug base. The principal drug is the one having a pKa of &gt;=6.5 and a solubility of &gt;=1g per 10ml of water at 25 deg.C. The ratios of the ionic absorbefacient and the nonionic absorbefacient to the main drug are 0.1-200 each, and the ratio of the ionic absorbefacient to the nonionic absorbefacient is preferably 2:8-8:2.
Spray solution to treat Athlete&#39;s foot:   An anti-fungal spray solution that can be used to treat and prevent athlete&#39;s foot. It contains an anti-fungal component and tea tree oil both dissolved in isopropyl alcohol.   The anti-fungal component is clotrimazol 1%. Tea tree oil in different strengths at least 5% used as a natural anti-fungal and antiseptic and also to overcome symptoms of athlete&#39;s foot. The solvent is isopropyl alcohol that will provide an antiseptic and dehydrating action.   The spray is used directly on the foot and between toes and also inside the shoes and socks.
FIELD: medicine, phytotherapy. SUBSTANCE: invention relates to the development of medicinal agent of vegetable origin and method of treatment of locomotor system diseases by phytosteaming therapy method. Species comprises 45 plants taken in the equal ratio. Invention proposes method of treatment of locomotor system diseases including phytosteaming therapy using the proposed species, intake of phytotea with this species and rubbing in a mixture of evaporated concentrate of the same species with 96% alcohol in spine and joints region. Method provides clearance of body at tissue and cellular level by effect on human body using curative steaming concentrate and phytobarrel. This agent can be used in prophylaxis and curative aim for treatment of locomotor system diseases. The proposed agent and method of treatment ensure to use the proposed procedure for treatment of different sicknesses of locomotor system, among them so called &#34;incurable&#34; ones, for example, rheumatic polyarthritis and Bekhterev&#39;s disease. EFFECT: improved method of treatment. 3 cl, 2 ex
PURPOSE: To provide a sunscreen compsn. which does not give physiological damages to the human body, which has a high sunburn protection factor and which is suitable to be locally applied on a skin of a human body. CONSTITUTION: This compsn. is obtd. by mixing an emulsifier, an oil phase and a water-based dispersion liquid of metallic oxide particles having &lt;0.2 μm average particle size under conditions to form an oil-in-water emulsion, and then mixed with a hydrophobic org. sunscreen. The amt. of the metallic oxide in the emulsion is up to 10 wt.%, and the amt. of the hydrophobic org. sunscreen is up to 7 wt.%. By combining the inorg. oxide emulsion and the hydrophobic org. sunscreen, a higher SPF is obtd. than the expected value of the sum of each effect.
FIELD: cosmetics. SUBSTANCE: invention relates to ready for using composition for keratin fibers oxidative composite and, in part, human keratin fibers, for example, hair. Composite comprises at least one oxidizing agent, at least one enzymatic system where enzyme relating to class of two- or tetra-electronic oxidoreductase or peroxidase is immobilized on material matrix obtaining by method &#34;sol-gel&#34; in medium suitable for staining. Invention relates also to method of staining using this composition. EFFECT: strongly staining agent with enhanced thermal stability. 41 cl
Systems and methods for evaluating competency of a healthcare professional are provided. Systems and methods for evaluating competence of a healthcare professional using linear narrative progress are provided. The system includes a virtual console and an evaluation tool. The virtual console is configured to present the clinical profile to the healthcare professional and to display a series of digital images and questions to the healthcare professional based on the clinical profile. The virtual console is also configured to receive a response to each question. The virtual console is further configured to display corrective instructions to the healthcare professional after receiving the response to the critical issue, wherein the subsequent digital image and issue are based on the corrective instructions. The evaluation tool is configured to evaluate the healthcare professional&#39;s interpretation of each of the plurality of digital images.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a chemical synthetic method of various optical isomers of ergothioneine.  &lt;P&gt;SOLUTION: In the method, a salt, an optically active salt if required, of Nα,Nα-dimethylated histidine ester is synthesized or used. The salt is treated with an alkyl, an alkenyl or an aryl halogeno thionoformate, especially phenyl halogeno thionoformate, in the presence of a base. A sulfur-containing substituent in the obtained compound is protected, and the protected compound is converted into a trimethyl ammonium compound, which is subsequently subjected to saponification or acid hydrolysis to liberate the desired ergothioneine. The method improves the yield and offers an excellent optical purity.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a measurement data processing system easily generating measurement data from ultrasonic data obtained by ultrasonic imaging and collecting and statistically processing the generated measurement data.  &lt;P&gt;SOLUTION: This measurement data processing system is provided with ultrasonic diagnostic equipment 101, and a measurement data processor 80 processing the measurement data transmitted from the ultrasonic diagnostic equipment 101 via a network 100. The ultrasonic diagnostic equipment 101 measures the ultrasonic data generated by the ultrasonic imaging based on examination information input from an operation section 8, adds measurement classification information corresponding to the measurement data produced by the measurement and the examination information thereto, and transmits them to the measurement data processor 80. Meanwhile, the measurement data processor 80 intensively stores the measurement data received from the ultrasonic diagnostic equipment 101. The measurement data processor searches measurement data added with the measurement classification information and search information obtained from a terminal device 201a, in the stored data, statistically processing the searched measurement data and generates the statistic data.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention provides a disease prevention control facility layout method based on fairness. The problem is expressed as a two-layer decision structure with leader-follower characteristics, and a two-layer two-target non-linear integer programming model is constructed accordingly. The upper level is a dual target planning model with budget constraints, where the primary goal is to minimize the probability of the user being denied service and the secondary goal is to minimize the maximum latency. While the lower layer is a user competition balance model generated by the user&#39;s selection of a service facility, which determines the allocation pattern of user demand at the disease control facility. The invention adopts Genetic Algorithm (GA) with elite strategy to solve the upper layer problem, and adopts successive average method (MsA) to solve the lower layer problem. The development of software adopts free R language, and experiments show that the method can be used for disease prevention and control facility planning based on fairness and also can provide reference for budget planning.
An animal model of coronary heart disease has been developed where myocardial infarct can be induced by altering the animal&#39;s diet. In all embodiments, this animal model is a result of reduced activity of scavenger receptor class BI (SR-BI) and apolipoprotein E (ApoE). In a preferred embodiment, the model is a result of crossbreeding two transgenic mouse lines: a knockout of SR-BI (SR-BI−/−) and an impaired ApoE expressor (hypoE). The impaired ApoE gene results in only 2-5% expression of ApoE and a reduction in cholesterol homeostasis. Resulting animals are predisposed to hypercholesterolemia but can live longer than a year on a normal low fat diet. Serum plasma levels can be significantly elevated by changing the animal&#39;s diet to one containing high levels of fat and cholesterol. Within a month on a high fat, high cholesterol diet, animals develop atherosclerosis and myocardial infarction occurs. Survival depends on the nature of the diet and the conditions of animal husbandry and can typically be around 20-30 days after administration of the modified diet depending on the specific conditions. Housing the animals alone or in groups significantly affects survival of these animals on a high fat diet. Analysis of B- and T-cell deficient SR-BI/ApoE/RAG2 triple knockout mice established that B- and T-lymphocytes do not play a key role in the pathophysiology of the SR-BI ApoE dKO model of human disease. These animal models can be used to study mechanisms and progression of CHD as a function of diet, treatment with drugs to be screened for efficacy or undesirable side effects, and social environmental effects.
125,618. Vickers, Ltd., Elia, G. E., and North, T. K. Sept. 13, 1916. Mines, marine. - Relates to submarine mines provided with extensible arms which, on impact with a ship, rotate relatively to the mine, causing the mine to be released and to rise by its buoyancy while the tension in the mooring-cable first cocks and then releases a spring striker, firing the mine. According to the invention, a &#34; driving &#34; member 1, Fig. 1, carrying the arm 10 is mounted in a bearing 2 m the bottom of the mine 4, and is attached at one end to the rod 6 of a spring striker 54, and at the other end to the @oring- cable by means of a shackle 8. The driving- member 1 is locked to a ring 22 against rotation by keys 23, and against longitudinal motion by radial bolts 11, Fig. 3, which are confined within the ring 22 by rollers 16 in the surrounding casing. The ring 22 is itself mounted without longitudinal freedom in the surrounding casing, and is locked against rotation by pins 26 in engagement with radial slots 25 in yokes 21, which are pressed by springs 28 against rollers 18: the yokes are indented to fit the surfaces of the rollers, forming a spring grip which yields only to a strong force. The casing surrounding these parts comprises an upper part 32 brazed to the mine and a cup-shaped lower part 33 secured to the upper part by bolts 35, a flanged steel ring 36&lt;1&gt; and a leather washer 36 being interposed to make the casing watertight. A disk 45 is secured to the top of the lower part by screws and is formed with a boss 47 which screws into the striker casing 50. The joint between the driving-member 1 and its bearing 2 on the lower part of the casing is made water-tight by an extensible corrugated lead tube 38, which is clamped to the bearing 2 and to a boss 37 on the driving-member by wires 39, Fig. 6, threaded through a block 41 and tightened by nuts 44. When the driving-member 1 is rotated relatively to the mine on impact of the mine with a ship, the bolts 11 are released from the rollers 16 and are wedged aside by the driving-member 1 as the mine rises by its buoyancy. The rising mine then compresses the striker spring until radial bolts 57 are wedged into a recess 58, releasing the striker 54 from the rod 6 and thus firing the mine. The arm 10 is passed transversely through the driving- member 1 and is then locked thereto by a pin 60. The outer part of the arm 10 is extended by a spring 65 when released from a gripping-device 62, 63, Fig. 5, by the dissolution of a plug 67. A screw 66 is screwed in the jaw 63 over the plug 67 to ensure that the jaw 63 shall grip the arm 10 tightly against the cradle 62 irrespective of the size of the plug 67.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a preventing agent of adult T-cell leukemia by inhibiting the onset of the adult T-cell leukemia, and a treating agent of the adult T-cell leukemia by improving the adult T-cell leukemia and a pharmaceutical composition by using them.  &lt;P&gt;SOLUTION: This preventing and treating agent of adult T-cell leukemia and its pharmaceutical composition are provided by using a process-treated material of rosemary, e.g. a crushed material, an extract or squeezed liquid of the rosemary as an active ingredient. Also, carnosol, carnosic acid and rosemarinic acid which are known components contained in the rosemary, can be used for the same purpose. Since the rosemary and the components contained in the rosemary are the components derived from a natural edible plant and used as the active ingredients, it is possible to be used as the medicine and a daily drug capable of being taken for a long period of time without anxiety.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT